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Abstract
Damage to the mitochondrial electron transport chain has been suggested to be an important factor in the pathogenesis of
a range of neurological disorders, such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, stroke and
amyotrophic lateral sclerosis. There is also a growing body of evidence to implicate excessive or inappropriate generation of
nitric oxide (NO) in these disorders. It is now well documented that NO and its toxic metabolite, peroxynitrite (ONOO3),
can inhibit components of the mitochondrial respiratory chain leading, if damage is severe enough, to a cellular energy
deficiency state. Within the brain, the susceptibility of different brain cell types to NO and ONOO3 exposure may be
dependent on factors such as the intracellular reduced glutathione (GSH) concentration and an ability to increase glycolytic
flux in the face of mitochondrial damage. Thus neurones, in contrast to astrocytes, appear particularly vulnerable to the
action of these molecules. Following cytokine exposure, astrocytes can increase NO generation, due to de novo synthesis of
the inducible form of nitric oxide synthase (NOS). Whilst the NO/ONOO3 so formed may not affect astrocyte survival, these
molecules may diffuse out to cause mitochondrial damage, and possibly cell death, to other cells, such as neurones, in close
proximity. Evidence is now available to support this scenario for neurological disorders, such as multiple sclerosis. In other
conditions, such as ischaemia, increased availability of glutamate may lead to an activation of a calcium-dependent nitric
oxide synthase associated with neurones. Such increased/inappropriate NO formation may contribute to energy depletion
and neuronal cell death. The evidence available for NO/ONOO3-mediated mitochondrial damage in various neurological
disorders is considered and potential therapeutic strategies are proposed. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Within the central nervous system (CNS), and
under normal conditions, nitric oxide (NO) appears
to have a number of important biochemical roles,
e.g. cGMP formation, following activation of guany-
late cyclase and the regulation of the glycolytic en-
zyme, glyceraldehyde-3-phosphate dehydrogenase [1^
3]. Furthermore, NO has been implicated to play an
important role in a number of physiological proc-
esses in the CNS, i.e. pain perception, synaptic plas-
ticity and learning [2].
NO itself is generated by nitric oxide synthase
(NOS), of which there are at least three isoforms
[2]. These enzymes catalyse, in the presence of mo-
lecular oxygen, tetrahydrobiopterin and other cofac-
tors, the conversion of arginine to NO plus citrulline
[2]. All CNS cells appear to have the ability to syn-
thesise NO, in vitro [2]. In general terms, neurones
synthesise NO via activation of the constitutive, cal-
cium-dependent, neuronal NOS isoform (nNOS or
NOS1), whilst astrocytes, and other glial cells, gen-
erate NO in a calcium-independent manner following
induction (de novo enzyme synthesis) of NOS (iNOS
or NOS2). A third isoform, eNOS (NOS3), is re-
ported in the CNS and has been assigned predomi-
nantly to the brain vasculature [2].
NO is a free radical and hence in many biological
systems it has a short half-life due to its reactivity
with other intracellular constituents, such as super-
oxide Oc32  [4]. The reaction between NO and Oc32
results in the formation of the peroxynitrite anion
(ONOO3), which is cytotoxic [5]. This reaction is
extremely favourable, so much so that NO can e¡ec-
tively compete with the superoxide dismutases for
Oc32 [4]. Since the toxicity associated with NO gen-
eration can, in many cases, be prevented by the scav-
enging of superoxide, formation of ONOO3 is there-
fore considered to be an important factor in causing
cellular damage [5].
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Despite the physiological roles attributed to NO,
excessive formation has been implicated in the patho-
genesis of certain neurological disorders [6,7]. Whilst
a number of mechanisms have been invoked to ex-
plain NO/ONOO3-mediated neurotoxicity, this re-
view will concentrate on the potentially important
interaction of these molecules with the mitochondrial
respiratory chain and how such mitochondrial dam-
age may be an important factor in the pathogenesis
of neurological conditions, such as Parkinson’s dis-
ease, Alzheimer’s disease, multiple sclerosis, ischae-
mia and amyotrophic lateral sclerosis.
2. The mitochondrial electron transport chain
The primary function of the mitochondrial elec-
tron transport chain (ETC) is ATP synthesis. The
ETC, present in the inner mitochondrial membrane,
is comprised of more than 70 polypeptide compo-
nents which are grouped into four enzyme complexes
(Fig. 1). The polypeptides that constitute complexes I
(NADH ubiquinone reductase), III (ubiquinol cyto-
chrome c reductase) and IV (cytochrome c oxidase)
are coded for by both nuclear and mitochondrial
DNA, whilst complex II (succinate ubiquinone re-
ductase) is exclusively coded for by nuclear DNA
[8]. In brief, transfer of reducing equivalents from
NADH or FADH2 to molecular oxygen is coupled
to the pumping of protons across the inner mito-
chondrial membrane resulting in the formation of a
proton gradient. Dissipation of this proton gradient
through the membrane sector of the mitochondrial
ATP synthase (complex V) induces a conformational
change in the active site of this enzyme which fa-
vours ADP phosphorylation and hence ATP synthe-
sis [9].
In view of the fundamental role the mitochondrial
ETC plays in energy metabolism, damage to one or
more of the respiratory chain complexes may lead to
an impairment of cellular ATP synthesis. However,
each of the complexes of the ETC exert varying de-
grees of control over respiration and substantial loss
of activity of an individual respiratory chain complex
may be required before ATP synthesis is compro-
mised [10]. Furthermore, within the brain, mitochon-
dria appear heterogeneous in nature and, depending
on cell type, display di¡erent threshold e¡ects, e.g. in
non-synaptic mitochondria, complex I has to be in-
hibited by approximately 72% before inhibition of
ATP synthesis occurs, whereas in synaptosomes the
threshold is 25% [10,11].
Fig. 1. Schematic of the mitochondrial electron transport chain. The four complexes of the mitochondrial electron transport chain,
present in the inner mitochondrial, membrane are shown. In addition, ATP synthetase, which is sometimes known as complex V, is
shown. Further details of this system are to be found in the text. Q and C represent the mobile electron carriers, ubiquinone and cy-
tochrome c, respectively.
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3. NO and the mitochondrial electron transport chain
3.1. Reversible complex IV inhibition
The interaction of NO with cytochrome oxidase
(complex IV) of the ETC has been known for almost
60 years [12]. Since NO resembles dioxygen and has
an unpaired electron, it has been used in electron
paramagnetic studies to elucidate the possible mech-
anisms involved for oxygen binding to complex IV.
Such investigations revealed that NO binds reversibly
to the Fe2 centre of cytochrome a3 and also to the
Cu2 centre of complex IV [13,14]. Whilst such stud-
ies provided useful information with regards to com-
plex IV structure and catalytic activity, the potential
(patho)physiological relevance of the interaction of
NO with complex IV was not considered until after
1987 when the importance of NO in biological sys-
tems became apparent [15].
Using biological systems, e.g. isolated heart mito-
chondria and synaptosomes, brief exposure to NO is
reported to lead to the rapid inhibition of mitochon-
drial respiration at the level of cytochrome oxidase.
[16,17]. Since, under the conditions employed, the
inhibition of oxygen consumption appeared to be
largely reversible, it has been postulated that NO
may be a physiological regulator of mitochondrial
respiration [17]. In support of this suggestion, Shen
et al. [18] reported that administration of an NOS
inhibitor to conscious dogs led to an increase in oxy-
gen consumption that could not be attributed to hae-
modynamic changes. However, further work is
needed to con¢rm or refute the suggested physiolog-
ical role for NO in controlling mitochondrial respi-
ration, particularly as complex IV may not display a
high degree of metabolic control over oxidative phos-
phorylation [10].
3.2. Irreversible complex IV damage
Exposure of cultured astrocytes to lipopolysac-
charide (LPS) and interferon-Q (IFN-Q) results in a
96-fold increase in iNOS activity [19]. Such treatment
is accompanied by a marked decrease in cellular oxy-
gen consumption which is only partially reversible by
the administration of a nitric oxide synthase inhibitor
or the scavenging of NO with oxyhaemoglobin [20].
Evaluation of the speci¢c activities of the respiratory
chain in homogenates prepared from these cells also
revealed a signi¢cant irreversible loss of complex IV
and complex II^III (see below) activity, which could
be prevented by the addition of an NOS inhibitor or
superoxide dismutase (+catalase to remove any hy-
drogen peroxide formed by superoxide dismutase)
[19]. These ¢ndings therefore suggest that this irre-
versible loss of activity is mediated by ONOO3.
Brief exposure of isolated brain mitochondria to
ONOO3 does not, however, result in a signi¢cant
loss of complex IV activity [21]. In contrast, exposure
of cultured neurones to ONOO3 followed by 24 h
incubation leads to a loss of complex IV activity [21].
The lack of an immediate e¡ect of ONOO3 upon
complex IV suggests that intracellular, time-depend-
ent, processes are involved for damage to this com-
plex to occur.
Complex IV activity has been shown to correlate
directly with the concentration of cardiolipin in the
inner mitochondrial membrane [22]. Cardiolipin, a
phospholipid rich in linoleic acid, is prone to perox-
idation [22]. Since ONOO3 may initiate lipid perox-
idation [23], it is possible that this process causes loss
of functional cardiolipin and a subsequent loss of
complex IV activity. In support of this, Trolox, a
vitamin E analogue and inhibitor of lipid peroxida-
tion has been shown to protect complex IV in LPS/
IFN-Q treated astrocytes [24]. However, as Trolox
can react directly with ONOO3 [25], it is likely
that protection also arises as a result of the direct
scavenging of ONOO3.
3.3. Loss of complex II^III activity
The integrated activity of succinate cytochrome c
reductase, i.e complex II^III of the ETC (Fig. 2), can
be measured in a single assay [19]. Exposure of iso-
lated brain mitochondria to exogenous ONOO3 re-
sults in an irreversible loss of activity of complex II^
III. [21]. Furthermore, in neurones exposed to
ONOO3 and analysed 24 h later, this component
of the ETC is again signi¢cantly decreased in activity
[21]. In addition, in cultured astrocytes exposed to
LPS/IFN-Q, there is an irreversible loss of complex
II^III activity [19]. Thus, in a range of systems, com-
plex II^III appears to be particularly vulnerable to
ONOO3 exposure. Assay of complex II^III requires
the endogenous quinone pool [26]. Recent observa-
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tions suggest that NO and possibly ONOO3 react
directly with ubiquinol [27]. This ¢nding may provide
an explanation for the irreversible loss of complex
II^III activity that occurs following ONOO3 expo-
sure and provokes the suggestion that oxidative loss
of ubiquinone may, under certain conditions, occur
in vivo. However, complex II itself also appears to be
directly susceptible to NO/ONOO3. Thus, direct ex-
posure of isolated heart mitochondria to ONOO3
and incubation of cultured oligodendrocytes with
an NO donor, results in loss of succinate dehydro-
genase (SDH ^ a component of complex II) activity
[28,29]. In order to evaluate our ¢ndings further with
isolated brain mitochondria, we have now assayed
complex II and complex III separately and observed
that brief exposure of brain mitochondria to
ONOO3 leads to loss of complex II activity only
[30].
3.4. Loss of complex I activity
Using isolated heart mitochondria, Radi et al.
demonstrated ONOO3-mediated impairment of oxy-
gen consumption with succinate as well as NAD-
linked substrates [28]. Enzymatic analysis of the com-
ponents of the respiratory chain indicated some loss
of rotenone sensitive NADH dehydrogenase (used in
this study to re£ect complex I) activity [28]. How-
ever, NADH dehydrogenase was not as sensitive as
SDH to the actions of ONOO3 [28]. Later studies,
Fig. 2. Neuronal mitochondrial damage as a result of astrocyte generation of NO and ONOO3. Exposure of astrocytes to cytokines
leads to an induction of iNOS and marked generation of NO and ONOO3 (formed from the reaction between NO and superoxide).
Mitochondrial damage may occur in these cells, but ATP levels are maintained due to an increase in glycolytic £ux. Further cellular
damage is minimised due to the relatively high glutathione (GSH) concentration. Di¡usion of NO and/or ONOO3 into a neighbour-
ing neurone may, if the cellular GSH concentration is low, lead to mitochondrial damage. Since these cells are unable to compensate
by increasing glycolysis, a cellular energy de¢ciency state ensues which may lead ultimately to cell death.
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again with isolated heart mitochondria, revealed that
NO caused reversible inhibition of complex I-, II-
and IV-dependent respiration [31]. However, it is
likely that this observation arises from NO-inhibiting
complex IV which, as a consequence, leads to a sec-
ondary impairment of electron transport and hence
glutamate/malate and succinate driven respiration.
Complex I in isolated brain mitochondria also ap-
pears to be relatively resistant to the direct actions of
ONOO3 [21]. However, we have noted that the sen-
sitivity of this complex to ONOO3 may be critically
dependent on the concentration of mitochondria uti-
lised in the incubations with ONOO3 and whether
respiratory substrates are present [30].
Induction of iNOS in astrocytes or brief exposure
of cultured neurones to ONOO3 does not result in
any loss of complex I activity [19]. In contrast, when
neurones are exposed to an NO donor for 24 h,
marked loss of complex I activity occurs in conjunc-
tion with a loss of complexes II^III and IV [32].
Under such conditions, there is also a marked loss
of the intracellular antioxidant, reduced glutathione
(GSH) [32]. When compared to neurones, astrocytes
appear resistant to exogenous ONOO3 [21]. How-
ever, depletion of astrocytic GSH renders the cells
more susceptible with marked complex I damage oc-
curring following subsequent ONOO3 exposure [33].
These ¢ndings imply that NO/ONOO3-mediated
complex I damage ensues only in the presence of a
marked GSH de¢ciency.
4. ONOO3 and the mitochondrial permeability
transition
Mitochondria may, upon exposure to oxidising
species, undergo a permeability transition, i.e certain
inner membrane proteins amalgamate to form a non-
speci¢c pore 2^3 nm in diameter that is speci¢cally
inhibited by cyclosporin A (CsA) [34]. Pore opening
leads to loss of the mitochondrial membrane poten-
tial (and thus ability to synthesise ATP), and an abil-
ity to sequester Ca2, both of which may be impor-
tant factors in necrotic cell death [35]. However, it
also appears that this mitochondrial permeability
transition is an important early event in programmed
cell death (apoptosis) [35,36]. Pore opening leads to
the release of mitochondrial cytochrome c, which
acts as a pro-apoptotic signal [35,36]. Pore opening
has been reported upon exposure of liver mitochon-
dria to reactive oxygen species [37] and ONOO3 [38].
The possible mechanisms involved in ONOO3-medi-
ated pore opening include: (1) ONOO3-induced
cross-linking of inner membrane protein thiol
groups, leading to protein amalgamation and pore
formation; (2) ONOO3-induced lipid peroxidation,
products of which are potent inducers of permeabil-
ity transition; and (3) ONOO3-induced mitochon-
drial respiratory chain dysfunction. It has been re-
ported that inhibition of the kidney mitochondrial
respiratory chain causes pore opening [39].
Whilst many of the phenomena associated with
opening of the mitochondrial permeability pore ap-
pear to be prevented by CsA, it has been reported
that peroxynitrite induces Ca2-independent swelling
of rat liver mitochondria that, under the conditions
employed, is insensitive to CsA [40]. Furthermore,
we have observed that exposure of isolated rat brain
mitochondria to ONOO3 causes an increase in state
4 (ADP rate-limiting) respiration that is insensitive to
CsA [30]. We attribute this to ONOO3-induced lipid
peroxidation that increases proton permeability of
the inner mitochondrial membrane [30]. Thus, the
precise experimental conditions and origin of mito-
chondria may dictate as to whether ONOO3 induces
the permeability transition.
5. Di¡erential cell susceptibility
It should be apparent, from the above, that mito-
chondria from di¡erent tissue sources display di¡er-
ential susceptibility to oxidising species, such as
ONOO3. However, it is also now becoming apparent
that, within the brain, there is a di¡erential suscept-
ibility of various brain cell types to NO/ONOO3
[21]. Factors such as the cardiolipin concentration
of the inner mitochondrial membrane, the cellular
antioxidant status and an ability to maintain energy
requirements, in the face of marked ETC damage,
may be important in dictating sensitivity towards
NO/ONOO3.
Induction of iNOS in astrocytes leads, as discussed
above, to marked damage to the ETC. However,
despite such damage, cell death does not occur [19].
The apparent resistance of these cells, in this situa-
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tion, appears to be mediated by a compensatory in-
crease in glycolysis, i.e there was a marked increase
in glucose consumption coupled with lactate forma-
tion [19].
In contrast to astrocytes, neurones appear to be
particularly vulnerable to the actions of ONOO3,
i.e. brief exposure of neurones to an exogenous
source of ONOO3 results in irreversible mitochon-
drial damage and cell death within 24 h [21]. Such
vulnerability may arise from an inability to sustain
cellular energy demands by glycolysis and an inferior
capacity to handle oxidising species such as ONOO3.
With regard to the latter suggestion, the intracellular
GSH concentration may be particularly important,
since ONOO3 favourably reacts with thiol-contain-
ing compounds [21,41]. Various lines of evidence are
now available to implicate a key role for GSH in
dictating cellular susceptibility to ONOO3 ; the as-
trocyte GSH concentration, in culture, appears to be
approximately double that of neurones cultured
under identical conditions [21], astrocytes display a
higher speci¢c activity of the rate-limiting enzyme of
GSH synthesis, Q-glutamyl cysteine synthetase [42],
GSH-depleted astrocytes display marked sensitivity
towards ONOO3 [33].
Another factor contributing to the relative resist-
ance of astrocytes to ONOO3 exposure may be their
superior concentration of K-tocopherol (vitamin E)
[42]. When compared to neurones, the concentration
of K-tocopherol in cultured astrocytes is reported to
be approximately 2.5 times greater [42].
6. Glutamate, NO and excitotoxicity
Stimulation of neuronal glutamate receptors can
transiently elevate the intracellular calcium concen-
tration [2]. Whilst some laboratories advocate an in-
volvement of NO in the process of neurotoxicity,
other groups have been unable to substantiate such
claims [43^45]. Such discrepancies, may relate to the
type of neurones used and the number of NOS-pos-
itive neurones that form the cell culture population.
The number of NOS-positive neurones present in
culture preparations may be dependent on a number
of factors, including the number of days in culture
[46,47]. Recently, using ‘mature’ neuronal cultures,
i.e. containing cells capable of generating NO, we
demonstrated that brief exposure to glutamate leads
to an NO-dependent loss in oxygen consumption,
ATP concentration, and mitochondrial complex II^
III and complex IV activities [48].
Furthermore, there was a signi¢cant loss in the
neuronal GSH concentration, which also could be
prevented by the inclusion of a NOS inhibitor [48].
Whether GSH depletion, under these conditions, is
due to an NO-dependent inhibition of cystine (a pre-
cursor of cysteine which is required for GSH syn-
thesis) uptake [49] or arises from the direct reaction
of NO/ONOO3 with intracellular GSH is not
known. However, these observations suggest that,
in the presence of su⁄cient NOS-positive neurones,
NO-mediated loss of mitochondrial function and cel-
lular GSH is an important factor in glutamate neuro-
toxicity. Since NOS-positive neurones actually ap-
pear to be resistant to glutamate receptor
activation, it has been proposed that these cells gen-
erate NO which is released to cause possible damage
to NOS-negative neurones in close proximity [47].
7. Astrocyte-derived NO and neurotoxicity
In view of the ability of astrocytes to generate NO
and ONOO3 without cell death occurring, it is pos-
sible that in certain neurological disorders, astrocytic
derived NO/ONOO3 may cause mitochondrial dam-
age to susceptible target cells, such as neurones (Fig.
2).
Whilst, induction of iNOS in mixed astrocyte/neu-
ronal co-cultures does not appear to cause immediate
neuronal cell death, it was observed that the ‘NO-
exposed’ neurones displayed increased sensitivity to-
wards glutamate [50]. Further studies, involving
mixed astrocyte/neuronal cultures, demonstrated
neuronal death 24^36 h after exposure to iNOS ex-
pressing astrocytes [51,52]. Investigations, utilising a
co-culture system in which neurones and iNOS ex-
pressing astrocytes are cultured close to (1 mm
apart), but not in contact with each other, demon-
strated signi¢cant neuronal mitochondrial damage
(complexes II^III and IV) and loss of ATP within
24 h [32,53]. Despite such mitochondrial damage,
neuronal cell death did not occur [53]. In view of
the marked sensitivity of neurones (when cultured
alone) towards NO and ONOO3, the lack of cell
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death appears, at ¢rst, to be paradoxical. However,
the co-culture of neurones with astrocytes leads to an
increase (U2) in the neuronal GSH concentration
[32]. This apparent upregulation of neuronal GSH
status appears to arise from the tra⁄cking of cys-
teine, a rate-limiting amino acid for GSH synthesis,
from astrocytes to neurones [54]. These observations,
therefore, lend further support to the critical role
GSH plays in dictating cellular susceptibility to
NO/ONOO3 and suggest that results obtained
from the ‘mono’ culture of neurones need to be in-
terpreted with caution. Furthermore, in neurological
conditions where induction of astrocyte iNOS may
occur, severe damage to target cells, such as neurones
and possibly oligodendrocytes, may not immediately
occur until the GSH status of such cells is compro-
mised. However, loss of GSH may eventually ensue
as a result of the direct reaction between GSH and
ONOO3 and impairment of GSH synthesis (an en-
ergy-dependent pathway) due to mitochondrial dam-
age.
8. Mitochondrial damage and cell death
Whether NO/ONOO3-mediated mitochondrial
damage is a direct cause of cell death is not estab-
lished. However, it is of interest to note that toxic
insults that cause severe mitochondrial damage, and
hence a rapid and marked energy failure, are associ-
ated with necrotic cell death [55]. Impairment of the
mitochondrial ETC may also play an important role
in the initiation of apoptosis, e.g. as a result of the
opening of the mitochondrial permeability transition
pore (see above). Furthermore, glutamate neurotox-
icity proceeds through the initiation of an apoptotic
pathway only if functional mitochondria are present,
suggesting an ATP requirement [55]. In support of
this, exposure of PC12 cells to ONOO3 and partial
inhibition of the mitochondrial respiratory chain
leads to cell death via apoptosis [56,57]. Whilst,
such studies implicate perturbation of mitochondrial
function in apoptosis, initiation of this process has
been reported in a human ¢broblast cell line lacking
functional mitochondria [58]. The implication of
these ¢ndings for neuronal cells is not clear. Further-
more, it is possible that these ¢broblasts could be
atypical in the sense that they could obtain substan-
tial ATP, for an apoptotic programme to proceed,
from glycolysis.
9. NO-mediated mitochondrial damage and
neurological disease
Damage to the mitochondrial respiratory chain
has been proposed to underlie the pathology of a
number of neurodegenerative disorders [59]. How-
ever, as pointed out above, loss of speci¢c activity
of a particular component of the ETC does not nec-
essarily equate to a cellular energy de¢ciency state,
i.e. due consideration must be given to the degree of
metabolic control a particular respiratory chain com-
plex exerts over oxidative phosphorylation [10,11].
9.1. Parkinson’s disease
Decreased complex I activity is reported in the
substantia nigra of post mortem samples obtained
from patients with Parkinson’s disease [60]. Further-
more, one study has also identi¢ed NADPH dia-
phorase (a putative marker for NOS activity) posi-
tive glial cells in the substantia nigra obtained from
such individuals [61]. Since loss of nigral GSH is also
considered to be an early and key event in the patho-
genesis of Parkinson’s disease [62], decreased scav-
enging of NO/ONOO3 may occur leading to the
possibility of mitochondrial damage. In view of the
apparent speci¢c loss of complex I activity, in Par-
kinson’s disease, it is also of note that this compo-
nent of the respiratory chain is particularly suscepti-
ble to the actions of ONOO3 when cellular GSH
levels are compromised [32,33].
9.2. Alzheimer’s disease
A decrease in complex IV activity has been re-
ported in the cerebral cortex of individuals who
died with Alzheimer’s disease [63]. Whilst the exact
mechanism for this loss of activity is not clear, it is
known that this enzyme complex is particularly sus-
ceptible to oxidative damage [3,19,21,22,24]. In addi-
tion, there is now evidence to suggest that NO me-
tabolism is a¡ected in Alzheimer’s disease. The glial
derived factor, S100-L, which is over expressed in this
condition, causes induction of astrocyte iNOS- and
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NO-mediated neuronal cell death in a co-culture sys-
tem [64]. Furthermore, L-amyloid is reported to ac-
tivate NOS in a substantia nigra/neuroblastoma hy-
brid cell line [65]. Analysis of post mortem material
has revealed, in Alzheimer brain tissue, the presence
of nitrotyrosine residues [66]. Formation of nitroty-
rosine is thought to occur as a result of the reaction
between ONOO3 and tyrosine residues in protein
and is not detectable in age-matched control brains
[66]. Studies using monospeci¢c antibodies to iNOS
have also revealed the presence of this isoform in
neuro¢brillary tangle-bearing neurones [67]. Despite
evidence for activation of NO metabolism in Alz-
heimer’s disease, analysis of the cerebrospinal £uid
(CSF) nitrite+nitrate (stable degradation products of
NO and ONOO3) concentration revealed levels in
Alzheimer’s patients comparable to controls [68].
Whilst this observation does not dismiss a role for
NO/ONOO3 in the aetiology of Alzheimer’s disease,
it implies that if formation of these molecules occurs,
it is of a localised nature and is of insu⁄cient mag-
nitude to cause a rise in CSF nitrite+nitrate concen-
tration.
9.3. Multiple sclerosis
Considerable evidence is also available to support
the suggestion that enhanced generation of NO and
ONOO3 occurs in multiple sclerosis (MS). Analysis
of CSF from patients in the active phase of MS
revealed an approximate 70% increase in the nitrite
plus nitrate concentration [69]. Further support for
the involvement of increased NO metabolism, in MS,
comes from post mortem studies which have detected
nitrotyrosine residues and elevated levels of mRNA
coding for iNOS [70,71]. NADPH diaphorase activ-
ity, which can re£ect NOS activity, has also been
detected in astrocytes associated with actively demye-
linating lesions [70].
Localised perturbation of the blood^brain barrier
is proposed to be an important event in MS [72]. NO
has been shown to cause a loss of barrier integrity in
a cell culture model of the blood^brain barrier [73].
Whether NO-mediated mitochondrial damage is the
cause of such damage remains to be established. Oth-
er experimental models also provide data to support
a role for NO/ONOO3 generation in MS; NO do-
nors have been shown to impair oligodendrocyte
(myelin generating cells) energy metabolism [29]
and cause reversible axonal conduction block (a
characteristic of MS), in vitro [74].
Whilst direct evidence for impairment of mito-
chondrial function in MS is not available, studies
upon N-acetyl aspartate metabolism support the
view that neuronal mitochondrial damage may be a
factor in the pathophysiology of MS. N-Acetyl as-
partate is believed to be synthesised exclusively in
neurones [75]. Furthermore, inhibition of the mito-
chondrial respiratory chain is associated with an im-
pairment of N-acetyl aspartate metabolism, both in
vitro and in vivo [76,77]. Studies utilising NMR spec-
troscopy have revealed a reduction in the signal at-
tributed to N-acetyl aspartate in MS plaques [78].
However, this decrease in N-acetyl aspartate concen-
tration appears, in some cases, to be reversible [78].
Whether such changes actually re£ect NO/ONOO3-
mediated damage to neuronal mitochondria is, as
yet, unclear.
10. Ischaemia/reperfusion
Ischaemic brain damage is accompanied by an en-
ergy de¢ciency state and selective neuronal loss [79].
Under such conditions, there is an increase in the
extracellular concentration of glutamate [2], which
may be neurotoxic due to activation of nNOS (see
above for further details). Excess NO generation, as
well as causing impairment of energy metabolism
and other metabolic processes, may also down regu-
late glutamate (NMDA) receptors [5], thereby mini-
mising the e¡ect of glutamate. In addition, NO can
cause vasodilation and hence increase cerebral blood
£ow to the infarcted area [2]. These e¡ects may pro-
vide an explanation for the contradictory results that
have been obtained when non-speci¢c NOS inhibi-
tors have been evaluated in various models of ischae-
mia [2].
Reperfusion, following ischaemia, may exacerbate
the generation of oxidising species, in particular,
superoxide [80]. Using a model of graded ischaemia,
loss of brain mitochondrial function, at the levels of
complexes I, II^III and ATP synthetase, has been
reported [81]. Reperfusion was accompanied by a
restoration of activity of these mitochondrial compo-
nents, followed, after 2 h, by a dramatic loss of com-
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plex IV activity [82]. The exact mechanism for this
loss of complex IV activity is not known, but could
involve the initiation of lipid peroxidation (see
above).
Ischaemia is also accompanied by the formation of
a gliotic scar which is comprised of reactive astro-
cytes [83]. Since a proportion of these astrocytes have
been shown to express iNOS [84], excessive genera-
tion of NO/ONOO3, by these cells, may be an im-
portant contributing factor to the mitochondrial
damage associated with ischaemia.
Excessive generation of NO is implicated to play a
role in the brain damage that occurs as a result of
perinatal asphyxia. Thus, inhibition of NOS is re-
ported to protect against hypoxic-ischaemia-medi-
ated neurotoxicity [85,86]. Recently, loss of brain
ATP concentration and mitochondrial complex II^
III and IV activity has been demonstrated in a rat
model of perinatal asphyxia [87]. Importantly, ad-
ministration of an NOS inhibitor, to the mothers,
prevented impairment of brain energy metabolism
in the hypoxic pups [87].
10.1. Amyotrophic lateral sclerosis
Oxidative stress is proposed to be an important
factor in the pathogenesis of amyotrophic lateral
sclerosis (ALS) (reviewed in [88]). With regards to
the familial form of this disease, mutations in
Cu,Zn superoxide dismutase (SOD-1) have been
identi¢ed [89]. Furthermore, it has been proposed
that such mutations increase ONOO3 formation,
due to decreased Oc32 scavenging, and enhance the
possibility of protein nitrosylation, i.e the active
site of SOD is altered allowing greater access of
ONOO3 to the copper centre and so favouring the
subsequent formation of a nitronium-like species
which nitrosylates tyrosine residues [4]. Immunocyto-
chemistry studies have also revealed, in the neuro¢la-
ment aggregates associated with ALS a close associ-
ation between SOD-1 and NOS activity [90]. Since,
light neuro¢lament is rich in tyrosine, it is proposed
that nitrotyrosine formation occurs which impairs
neuro¢lament assembly and ultimately leads to mo-
toneuron death [90]. Recently, increased nitrotyro-
sine immunoreactivity has been demonstrated in mo-
tor neurones of both sporadic and familial ALS,
suggesting that ONOO3-mediated oxidative damage
may play a role in the pathogenesis of both forms of
the disease [91]. Some evidence is now available to
suggest that mitochondrial function is impaired in
ALS. Thus, a signi¢cant reduction in complex IV
activity is reported in the spinal cord (ventral, lateral
and dorsal regions) of patients with sporadic ALS
[92]. In addition, studies with a transgenic mouse
model of ALS also suggest that axonal transport of
organelles, in particular mitochondrial transport, is
impaired and may be an important factor in ALS
[93].
11. Therapeutic considerations
In view of the importance of antioxidants, in par-
ticular GSH, it is possible that agents that are capa-
ble of increasing the cellular concentration of this
molecule may prove to be of therapeutic nature. Sim-
ilarly, given the apparent key role of cardiolipin in
maintaining optimum complex IV activity, preven-
tion of lipid peroxidation or supplementation with
linoleic acid may be of therapeutic use. It is also
possible that some existing treatments, for which
the mode of action is currently poorly understood,
may involve alterations in NO metabolism. Such an
example may be interferon-L which is used in the
treatment of certain forms of MS [94]. Recently, we
have found that preparations containing interferon-L
impair the ability of astrocytes to induce NOS and
hence generate NO when subsequently exposed to
cytokines, such as interferon-Q [95].
12. Conclusions
There is now evidence, both direct and indirect, to
support the concept that mitochondrial damage oc-
curs in a range of neurological disorders, such as
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, ischaemia/reperfusion and amyotrophic lat-
eral sclerosis. Furthermore, data is available to sug-
gest increased generation of NO and ONOO3 in
these conditions. Whether NO/ONOO3 generation
is the direct cause of the mitochondrial damage re-
mains to be demonstrated. However, data, from a
wide range of relevant experimental models, clearly
show that NO/ONOO3 causes damage to the mito-
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chondrial ETC. Further understanding of the inter-
action of these molecules with the mitochondrial
ETC may lead to e¡ective therapeutic strategies for
the neurological disorders discussed. However, such
studies must pay particular attention to the in£uence
cellular environments have on dictating mitochon-
drial susceptibility.
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